2-氯甲基-5-甲基-1,3,4-噁二唑 | 3914-42-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-氯甲基-5-甲基-1,3,4-噁二唑
• 中文别名: 2-(3-碘苯基)喹啉-4-羧酸；2-氯甲基-5-甲基-1,3,4-恶二唑；2-(氯甲基)-5-甲基-1,3,4-恶二唑
• 英文名称: 2-(chloromethyl)-5-methyl-1,3,4-oxadiazole
• 英文别名: 2-methyl-1,3,4-oxadiazol-5-ylmethyl chloride
• CAS: 3914-42-9
• 化学式: C₄H₅ClN₂O
• mdl: MFCD06655111
• 分子量: 132.549
• InChiKey: KJLQSWULHSLSOM-UHFFFAOYSA-N

物化性质

• 熔点：
  135-137 °C
• 沸点：
  211.7±42.0 °C(Predicted)
• 密度：
  1.291±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P270,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P405,P501
• 危险品运输编号：
  3265
• 危险性描述：
  H302,H314
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(chloromethyl)-5-methyl-1,3,4-oxadiazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(chloromethyl)-5-methyl-1,3,4-oxadiazole
CAS number: 3914-42-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H5ClN2O
Molecular weight: 132.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯甲基-5-甲基-1,3,4-噁二唑 在 sodium hydride 、 水 、 氯化铵 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以25.7%的产率得到tert-butyl 3-((5-methyl-1,3,4-oxadiazol-2-yl)methoxy)azetidine-1-carboxylate
  参考文献：
  名称：

  WO2008/24892

  摘要：

  公开号：
• 作为产物：
  描述：

  N’-(2-氯乙酰基)乙酰肼 在 三氯氧磷 作用下， 以70%的产率得到2-氯甲基-5-甲基-1,3,4-噁二唑
  参考文献：
  名称：

  ArbeitenüberPhosphorsäure-andThiophosphorsäureestermit einem heterocyclischen Subitententen。5. Mitteilung。2-烷氧基和2-烷硫基5-氯代甲基-1--1、3,4-噻二唑，2-烷基5-氯代甲基1-1,3,4-恶二唑和芳基酮硫代和二硫代磷酸-O，O-二烷基-S-[（2-烷氧基和2-烷硫基-1，3，4-噻二唑-5-基）-甲基] -bzw。-S-[（2-烷基1-1，3，4-恶二唑-5-基）-甲基酯†

  摘要：

  2-烷氧基-5-氯甲基1-1,3,4-噻二唑是通过将3-氯乙酰基-硫代咔唑O-烷基酯与浓硫酸，2-烷基硫基5-氯甲基1-1,3进行闭环制备的在一步合成中，直接从二硫代咔唑烷基酯中的4-噻二唑与氯乙酰氯在苯中合成，从1-氯乙酰基-2-酰基中省略了3-氯乙酰基衍生物和2-烷基-5-氯-甲基1-1,3,4-恶二唑-肼与POCl 3。这三种类型的氯甲基杂环容易与硫代和二硫代磷酸的盐反应形成相应的O，O-二烷基-S-[（（2-烷氧基和2-烷硫基-1,3,4-噻二唑-5-基）-甲基]-和-S-[（2-烷基1-1,3,4-恶二唑-5-基）-甲基]-硫代和-二硫代磷酸酯。

  DOI：

  10.1002/hlca.19720550616

文献信息

• NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS
  申请人：INVENTIVA

  公开号：US20170066717A1

  公开（公告）日：2017-03-09

  The invention relates to compounds of formula (I). where R, R 1 , R 2 , n, A and Cy have the meanings indicated in the description. The compounds of formula (I) are Nurr-1 modulators.

  这项发明涉及式(I)的化合物。 其中R、R1、R2、n、A和Cy的含义如描述中所示。 式(I)的化合物是Nurr-1调节剂。
• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINE EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ANDREWS STEVEN W

  公开号：WO2018071447A1

  公开（公告）日：2018-04-19

  Provided herein are compounds of the Formula I and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文件提供了公式I的化合物以及立体异构体和药用可接受的盐或溶剂化物，其中A、B、X1、X2、X3、X4、环D和E具有说明书中给出的含义，它们是RET激酶的抑制剂，可用于治疗和预防可通过RET激酶抑制剂治疗的疾病，包括与RET相关疾病和失调。
• SUBSTITUTED OXOPYRIDINE DERIVATIVES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20170298052A1

  公开（公告）日：2017-10-19

  The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

  这项发明涉及替代氧吡啶衍生物及其制备方法，以及将其用于生产治疗和/或预防疾病的药物，特别是心血管疾病，优选为血栓性或血栓栓塞性疾病，水肿，以及眼科疾病。
• [EN] COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：PRAXIS PREC MEDICINES INC

  公开号：WO2018148745A1

  公开（公告）日：2018-08-16

  The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

  本发明部分涉及融合的杂环基化合物和组合物，用于预防和/或治疗与电压门控钠离子通道异常功能相关的疾病或症状，例如异常的晚期/持续性钠电流。本文还提供了治疗与钠离子通道异常功能相关的疾病或症状的方法，包括德拉维特综合征或癫痫。
• [EN] TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS<br/>[FR] TRIAZA-SPIRODÉCANONES UTILISÉES EN TANT QU'INHIBITEURS DE DDR1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017005583A1

  公开（公告）日：2017-01-12

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

  本发明涉及式(I)的化合物或其药用盐，其中L和R1至R5如本文所述，以及它们的制备方法、包含它们的药物组合物，以及它们作为药物的用途。